prostate cancer, and identify the mechanisms driving ncRNA expression.
This project will have a broad significance by establishing an
integrative approach for ncRNA discovery which can be applied to a
variety of cancers. Comparison of the results may illustrate patterns
of protease activity in specific types of cancer or individual protease
substrates as biomarkers, which would provide a basis for further
clinical development.
-- Michael Pluth -- Massachusetts Institute of Technology
Dr. Pluth's study hopes to design and develop reversible fluorescent
sensors for nitric oxide (NO) by using iron for use in live cells for
the detection and quantification of intracellular levels of NO. NO has
shown to play an active role in biological signaling and current
sensors prohibit real-time quantification of nitric oxide
concentrations. This study will further the understanding of the
unique dichotomous role of nitric oxide in carcinogenesis and tumor
growth prevention, and will ideally contribute to the long-term goal of
developing new, non-invasive strategies for the early detection of
cancer.
-- Joe Shuga -- University of California, Berkeley
Using microfluidic technologies developed by the U.C. Berkeley's
Mathies lab, Dr. Shuga seeks to conduct single cell genetic analysis of
several genes parallel in individual human cells. By sequencing genes
from single cells, it will be possible to detect key mutations in rare
cells such as normal or cancer stem cells. The ability to sequence
genes linked to cancer in single cells will aid in early detection of
biomarkers, monitoring of minimal residual disease, and understanding
cancer etiology.
-- Robert W. Sprung -- Vanderbilt Ingram Canc
'/>"/>
| SOURCE Canary Foundation Copyright©2008 PR Newswire. All rights reserved |